AU2020292246A1 - Human antibodies to bone morphogenetic protein 6 - Google Patents

Human antibodies to bone morphogenetic protein 6 Download PDF

Info

Publication number
AU2020292246A1
AU2020292246A1 AU2020292246A AU2020292246A AU2020292246A1 AU 2020292246 A1 AU2020292246 A1 AU 2020292246A1 AU 2020292246 A AU2020292246 A AU 2020292246A AU 2020292246 A AU2020292246 A AU 2020292246A AU 2020292246 A1 AU2020292246 A1 AU 2020292246A1
Authority
AU
Australia
Prior art keywords
antibody
antigen
bmp6
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020292246A
Other languages
English (en)
Inventor
Sarah J. Hatsell
Vincent J. Idone
Andrew J. Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2020292246A1 publication Critical patent/AU2020292246A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020292246A 2019-06-12 2020-06-09 Human antibodies to bone morphogenetic protein 6 Pending AU2020292246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860597P 2019-06-12 2019-06-12
US62/860,597 2019-06-12
PCT/US2020/036771 WO2020251924A1 (en) 2019-06-12 2020-06-09 Human antibodies to bone morphogenetic protein 6

Publications (1)

Publication Number Publication Date
AU2020292246A1 true AU2020292246A1 (en) 2022-01-27

Family

ID=71944214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020292246A Pending AU2020292246A1 (en) 2019-06-12 2020-06-09 Human antibodies to bone morphogenetic protein 6

Country Status (7)

Country Link
US (1) US12612452B2 (cg-RX-API-DMAC10.html)
EP (1) EP3983436A1 (cg-RX-API-DMAC10.html)
JP (2) JP7807238B2 (cg-RX-API-DMAC10.html)
AU (1) AU2020292246A1 (cg-RX-API-DMAC10.html)
CA (1) CA3141266A1 (cg-RX-API-DMAC10.html)
MA (1) MA56203A (cg-RX-API-DMAC10.html)
WO (1) WO2020251924A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120888004B (zh) * 2025-09-30 2026-04-03 齐鲁制药有限公司 包含索特西普和其变体的组合物以及相关方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
AU2016211890B2 (en) 2008-11-13 2018-03-22 The General Hospital Corporation Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6
US20140086919A1 (en) 2012-09-24 2014-03-27 Herbert Y. Lin Methods and compositons for regulating iron homeostasis by modulation of bmp-6
AR093620A1 (es) * 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists

Also Published As

Publication number Publication date
JP2025138816A (ja) 2025-09-25
US12612452B2 (en) 2026-04-28
MA56203A (fr) 2022-04-20
US20220251184A1 (en) 2022-08-11
CA3141266A1 (en) 2020-12-17
JP7807238B2 (ja) 2026-01-27
EP3983436A1 (en) 2022-04-20
JP2022537142A (ja) 2022-08-24
WO2020251924A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
JP7699191B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
US20230192831A1 (en) Human Antibodies to GREM1
US10526403B2 (en) Anti-activin A antibodies and uses thereof
AU2015264189B2 (en) Human antibodies to Middle East Respiratory Syndrome -Coronavirus spike protein
AU2018202814B2 (en) Anti-PDGFR-beta antibodies and uses thereof
CA2993976A1 (en) Anti-angptl8 antibodies and uses thereof
EP4103617A1 (en) Anti-acvr1 antibodies and uses thereof
JP2025138816A (ja) 骨形成タンパク質6に対するヒト抗体
WO2026006740A1 (en) Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
NZ716854B2 (en) Anti-activin a antibodies and uses thereof
WO2014137674A1 (en) Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense